ArticleInternational journal of public health2020
Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia.
Article in International journal of public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2021Pooled it
- Temporal trends in the epidemiology of primary biliary cholangitis in the public healthcare system of Brazil: a large population-based study.Lancet regional health. Americas · 2026Article
- Adipokine profiles reflect metabolic dysfunction but not fibrosis in patients with primary biliary cholangitis.World journal of hepatology · 2026Article
- Metabolic syndrome and its individual components but not MASLD are associated with advanced fibrosis in primary biliary cholangitis.Therapeutic advances in gastroenterology · 2026Article
- The treatment of primary biliary cholangitis: from shadow to light.Therapeutic advances in gastroenterology · 2024Review
- Risk Stratification in Primary Biliary Cholangitis.Journal of clinical medicine · 2023Review
- Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice.Journal of personalized medicine · 2022Review
- Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients.Journal of personalized medicine · 2021Article
- External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis.Canadian journal of gastroenterology & hepatology · 2021Article
- Primary biliary cholangitis: a summary of pathogenesis and therapies.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine both the incidence and the prevalence of primary biliary cholangitis (PBC) in Eastern Slovakia and to describe its clinical course and the response to ursodeoxycholic acid (UDCA).
methodsWe recorded data of patients with PBC, who were followed up in gastroenterology and hepatology centers in Eastern Slovakia during the period from June 30, 1999, through June 30, 2019.
resultsThe annual incidence of PBC varied from 0.7 to 1.5 cases per 100,000 inhabitants between 2014 and 2018. PBC prevalence steadily increased from initial 10.2 cases per 100,000 inhabitants in 2014 to 14.9 cases per 100,000 inhabitants in June 2019. The mean age at the time of diagnosis was 56.3 ± 10.9 years. 95.7% of patients were females, and female/male gender ratio was 22.3:1. In June 2019, prevalence in the female population was 28 cases per 100,000 women. At the time of diagnosis, three-quarters of patients were symptomatic and 10% of patients had liver cirrhosis. The mean follow-up was 7.3 ± 5.2 years. Response to UDCA was observed in 72.1% of patients. Patients with higher baseline alkaline phosphatase (ALP) levels, liver cirrhosis at entry or at the end of follow-up and women younger than 45 years responded worse to UDCA. One-quarter of patients had liver cirrhosis at the end of follow-up. During follow-up, 1.6% of patients underwent liver transplantation and 5.5% of patients died. Five-year and 10-year liver-related mortalities were 2.7% and 4.3%, respectively.
conclusionPBC prevalence in Eastern Slovakia is increasing, and most of the patients respond to therapy with UDCA.
Indexed as
Identifiers
32500239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.